查看文章

Preliminary data from randomized trials with metabolic outcomes have shown that treatment with dipeptidyl peptidase‐4 inhibitors (DPP4i) could be associated with a reduced incidence of major cardiovascular events (MACE). The present meta‐analysis is aimed at verifying this protective effect, collecting all available data from randomized trials.

A comprehensive search for published and unpublished trials with a duration ≥24 weeks comparing DPP4i with placebo or other drugs was performed, retrieving all MACE reported as serious adverse events together with death from any cause. Mantel–Haenzel odds ratio (MH–OR) was calculated with random effect models for MACE, myocardial infarction, stroke and mortality. When available, effects on glycated haemoglobin, lipid profile and blood pressure were also assessed and used for the estimation of the modification of risk for myocardial infarction …